The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Move to accelerate cancer care expansion across India
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated
